Pfizer Historical Income Statement
| PFE Stock | USD 25.82 0.39 1.49% |
Historical analysis of Pfizer income statement accounts such as Other Operating Expenses of 28.8 B, Operating Income of 3.2 B, EBIT of 3.1 B or Ebitda of 15.4 B can show how well Pfizer Inc performed in making a profits. Evaluating Pfizer income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pfizer's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Pfizer Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pfizer Inc is a good buy for the upcoming year.
Pfizer |
About Pfizer Income Statement Analysis
Pfizer Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pfizer shareholders. The income statement also shows Pfizer investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Pfizer Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Pfizer Inc generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Pfizer Inc minus its cost of goods sold. It is profit before Pfizer operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pfizer Inc. It is also known as Pfizer overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Pfizer Inc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Pfizer Inc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Pfizer's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. At present, Pfizer's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 30.4 B, whereas Other Operating Expenses is forecasted to decline to about 28.8 B.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 50.5B | 66.0B | 28.8B | 30.4B | Total Revenue | 81.3B | 100.3B | 58.5B | 39.5B |
Pfizer income statement Correlations
Click cells to compare fundamentals
Pfizer Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pfizer income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 171.9K | 4.7B | 5.2B | 5.1B | 6.3B | 6.6B | |
| Interest Expense | 1.6B | 1.4B | 1.3B | 1.2B | 2.2B | 2.3B | |
| Total Revenue | 51.8B | 41.9B | 81.3B | 100.3B | 58.5B | 39.5B | |
| Gross Profit | 41.5B | 33.2B | 50.5B | 66.0B | 28.8B | 30.4B | |
| Other Operating Expenses | 37.8B | 33.1B | 61.1B | 63.1B | 55.1B | 28.8B | |
| Operating Income | 15.1B | 10.6B | 24.8B | 40.0B | 3.4B | 3.2B | |
| Ebit | 19.7B | 8.5B | 25.6B | 36.0B | 3.3B | 3.1B | |
| Ebitda | 19.7B | 13.2B | 30.8B | 41.0B | 9.6B | 15.4B | |
| Cost Of Revenue | 10.2B | 8.7B | 30.8B | 34.3B | 29.7B | 31.2B | |
| Total Operating Expenses | 27.6B | 24.5B | 30.2B | 28.7B | 25.5B | 19.8B | |
| Income Before Tax | 17.7B | 7.5B | 24.3B | 34.7B | 1.1B | 1.0B | |
| Total Other Income Expense Net | 2.5B | (3.6B) | (2.7B) | (2.5B) | (2.3B) | (2.4B) | |
| Net Income | 16.3B | 7.0B | 22.0B | 31.4B | 2.1B | 2.0B | |
| Income Tax Expense | 1.4B | 477M | 1.9B | 3.3B | (1.1B) | (1.1B) | |
| Selling General Administrative | 12.1B | 9.8B | 10.7B | 10.9B | 11.1B | 12.9B | |
| Research Development | 8.7B | 9.4B | 13.8B | 11.4B | 10.7B | 8.2B | |
| Net Income Applicable To Common Shares | 16.3B | 9.6B | 22.0B | 31.4B | 36.1B | 37.9B | |
| Discontinued Operations | 4M | 2.6B | (434M) | 6M | 5.4M | 5.1M | |
| Net Income From Continuing Ops | 16.3B | 7.0B | 22.5B | 31.4B | 2.2B | 2.1B | |
| Non Recurring | 747M | 600M | 802M | 2.3B | 2.1B | 1.3B | |
| Selling And Marketing Expenses | 2.7B | 2.3B | 1.8B | 2B | 3.7B | 2.2B | |
| Non Operating Income Net Other | 4.5B | (663M) | 4.9B | (217M) | (249.6M) | (262.0M) | |
| Tax Provision | 1.4B | 477M | 1.9B | 3.3B | (1.1B) | (1.1B) | |
| Interest Income | 226M | 538M | 560M | 1.8B | 1.6B | 924.4M | |
| Extraordinary Items | 326M | 2.6B | (434M) | 6M | 5.4M | 5.1M | |
| Net Interest Income | (1.3B) | (1.4B) | (1.3B) | (987M) | (585M) | (614.3M) | |
| Reconciled Depreciation | 6.0B | 4.8B | 3.7B | 3.6B | 6.3B | 4.2B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Dividend Share 1.67 | Earnings Share 0.75 | Revenue Per Share 10.493 | Quarterly Revenue Growth 0.312 |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.